Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of DZD9008 versus platinum-doublet chemotherapy in previously untreated EGFR exon 20 insertion-mutant advanced or metastatic non-small cell lung cancer
CTR20223235Phase 3Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Dec 2022; status: active.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20223235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223235.